Physiology and Pharmacology of Neurotransmitter Transporters
- PMID: 34190339
- DOI: 10.1002/cphy.c200035
Physiology and Pharmacology of Neurotransmitter Transporters
Abstract
Regulation of the ability of a neurotransmitter [our focus: serotonin, norepinephrine, dopamine, acetylcholine, glycine, and gamma-aminobutyric acid (GABA)] to reach its receptor targets is regulated in part by controlling the access the neurotransmitter has to receptors. Transporters, located at both the cellular plasma membrane and in subcellular vesicles, carry a myriad of responsibilities that include enabling neurotransmitter release and controlling uptake of neurotransmitter back into a cell or vesicle. Driven largely by electrochemical gradients, these transporters move neurotransmitters. The regulation of the transporters themselves through changes in expression and/or posttranslational modification allows for fine-tuning of this system. Transporters have been best recognized as targets for psychoactive stimulants and remain a mainstay target of primarily central nervous system (CNS) acting drugs for treatment of debilitating diseases such as depression and anxiety. Studies reveal, however, that transporters are found and functional in tissues outside the CNS (gastrointestinal and cardiovascular tissues, for example). The importance of neurotransmitter transporters is underscored with discoveries that dysfunction of transporters can cause life-changing disease. This article provides a high-level review of major classes of both plasma membrane transporters and vesicular transporters. © 2021 American Physiological Society. Compr Physiol 11:2279-2295, 2021.
Copyright © 2021 American Physiological Society. All rights reserved.
References
-
- Aggarwal S, Mortensen OV. Overview of monoamine transporters. Curr Protoc Pharmacol 79: 12.16.1-12.16.17, 2017. DOI: 10.1002/cpph.32.
-
- Alfadhel M, Nashabat M, Qahtani HA, Alfares A, Mutairi FA, Shaalan HA, Douglas GV, Wierenga K, Juusola J, Alrifai MT, Arold ST, Alkuraya F, Ali QA. Mutation in SLC6A9 encoding a glycine transporter causes a novel form of non-ketotic hyperglycinemia in humans. Hum Genet 135: 1263-1268, 2016. DOI: 10.1007/s00439-016-1719-x.
-
- Al-Khrasani M, Mohammadzadeh A, Balogh M, Kiraly K, Barsi S, Hajnal B, Koles L, Zadori ZS, Harsing LG. Glycine transporter inhibitors: A new avenue for managing neuropathic pain. Brain Res Bull 152: 143-158, 2019. DOI: 10.1016/j.brainresbull.2019.07.008.
-
- Anne C, Gasnier B. Vesicular neurotransmitter transporters: Mechanistic aspects. Curr Top Membr 73: 149-174, 2014. DOI: 10.1016/B978-0-12-800223-0.00003-7.
-
- Aragon C, Lopez-Corcuera B. Structure, function and regulation of glycine neurotransporters. Eur J Pharmacol 479: 249-262, 2003. DOI: 10.1016/j.ejphar.2003.08.074.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
